July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Effects of twice per day KN-A01, a modified hyaluronic acid based hydrogel, for the treatment of dry eye syndrome in dog patients
Author Affiliations & Notes
  • Yu Yu
    Pleryon Therapeutics, Kowloon, Hong Kong
    Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong, China
  • Derek Chow
    Veterinary Specialty Hospital, Hong Kong, China
  • Woojin Back
    Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong, China
  • Jing Xu
    Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong, China
  • Ying Chau
    Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong, China
  • Footnotes
    Commercial Relationships   Yu Yu, Pleryon Therapeutics (I); Derek Chow, None; Woojin Back, None; Jing Xu, None; Ying Chau, Pleryon Therapeutics (I)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3824. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yu Yu, Derek Chow, Woojin Back, Jing Xu, Ying Chau; Effects of twice per day KN-A01, a modified hyaluronic acid based hydrogel, for the treatment of dry eye syndrome in dog patients. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3824.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : KN-A01 is a novel intillable hydrogel based on modified hyaluronic acid. In a previous rabbit study, we found that more than 30% of KN-A01 was able to retain on the eye surfaces over 5 hours. In this study, we evaluate its therapeutic effect in combination with cyclosporine in dog patients with dry eye syndrome.

Methods : Dog patients that are diagnosed with dry eye syndrome and have been on 4-6 times a day conventional artificial tear in combination with cyclosporine treatment for over 1 year was enrolled in the study. Based on the clinical outcome of the previous cyclosporine treatment, patients were divided into two groups, cyclosporine responsive and cyclosporine nonresponsive. Both groups were switched to twice a day KN-A01 in combination with cyclosporine. Seven clinical signs including blephorospasm, discharge, corneal staining and Schirmer’s test were scored and conjunctival cells were collected by indentation cytology (IC) before the initiation of the study and 1 month after the treatment with KN-A01. The cells collected by IC were evaluated by immunohistology for MMP-9 positive cells.

Results : KN-A01 was well tolerated by all dogs and well received by dog owners because of the reduced number of instillation required. The preliminary results show that KN-A01 was able to maintain the therapeutic effect over the test period (Figure 1). For some dogs, clinical signs were improved after the 1 month treatment.

Conclusions : KN-A01 can potentially be useful for treating dry eye diseases because of its therapeutic effect and less frequent dosing.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Examples showing the effect of KN-A01 on three of the seven clinical signs. (Res: responsive to cyclosporine, Non: nonresponsive to cyclosporine, Before: before KN-A01 treatment, After: after 1 month treatment of KN-A01)

Examples showing the effect of KN-A01 on three of the seven clinical signs. (Res: responsive to cyclosporine, Non: nonresponsive to cyclosporine, Before: before KN-A01 treatment, After: after 1 month treatment of KN-A01)

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×